Drug Trial Radar · NCT06151964
A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
166
Actual
Start
Sep 29, 2023
Primary completion
Jan 29, 2027
Study completion Jan 29, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its associated co-morbidities. Co-administration of AZD9550 and AZD6234 is currently being evaluated in participants living with obesity and overweight without T2DM in an ongoing Phase 2b study. The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 monotherapy in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body (Parts A-D). In addition, the study will investigate the safety and tolerability of co-administration of AZD9550 and AZD6234 in participants living with T2DM with obesity or overweight aged 18 through 75 years (Part E), and safety and tolerability for different titration regimens for AZD9550 in participants living with obesity, but without T2DM, aged 18 through 75 years (Part F).
Conditions
- Overweight and Obesity
Interventions
AZD9550Drug
Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part F: Doses of AZD9550 that increase every 4 weeks or every 2 weeks and then every 4 weeks
placeboDrug
Matching administration volumes for SC injection. For Part E placebo two injections of two different placebos.
AZD9550 and AZD6234Drug
Part E: Doses of AZD9550 and AZD6234 that increase every 2 weeks, then every 4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.Time frame: Day - 35 to Day 261
- Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters.Time frame: Day - 35 to Day 261
- Number and percentage of participants with clinically significant changes in ECG parameters.Time frame: Day - 35 to Day 261
- Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory ParametersTime frame: Day - 35 to Day 261
- Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Maximum observed concentration of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Time to maximum observed concentration of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Apparent oral clearance of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Apparent volume of distribution of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Ratio for AUC of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
- Ratio for Cmax of AZD9550 following repeat weekly SC dosesTime frame: Day 1 to Day 65
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Graz, Austria
Research Site
Vienna, Austria
Research Site
Surrey, British Columbia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Sarnia, Ontario, Canada
Research Site
Stouffville, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Magdeburg, Germany
Research Site
Neu-Ulm, Germany
Research Site
Neuss, Germany
Research Site
Fukuoka, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Suita-shi, Japan
Research Site
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.